Результаты поиска

Cytokine-Induced Killer Cells: A Unique Platform for Adoptive Cell Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation.

BackgroundImmunotherapies in general, and cellular immunotherapies, in particular are becoming increasingly integrated into current personalized cancer treatment, though still facing some obstacles in the allogeneic hematopoietic stem cell transplantation (HSCT) setting.SummaryThe concept of isolating immune effector cells, expanding their numbers, enhancing their anticancer capabilities by modifying them without increasing their alloreactive potential is the mainstay of adoptive cellular immunotherapy after allogeneic HSCT. In this context, cytokine-induced killer (CIK) cells, a polyfunctiona

The Contribution of Spanish Science to Patents: Medicine as Case of Study.

Investments in research and development (R&D) and innovation are expensive, and one wishes to be assured that there is positive feedback and to receive guidance on how to direct investments in the future. The social or economic benefits of investments in R&D are of particular interest to policymakers. In this regard, public expense in research, especially through universities, is sometimes being questioned. This paper establishes a measure of how research in Spain, and specifically in its universities, is involved. In this study, we have analyzed all the literature cited in the period 1998-201

Polycythemia Vera: Barriers to and Strategies for Optimal Management.

Polycythemia vera (PV) is a subtype of myeloproliferative neoplasms characterized by impaired quality of life and severe complications. Despite the increasingly in-depth knowledge of this condition, it necessitates a multifaceted management approach to mitigate symptoms and prevent thrombotic and hemorrhagic events, ensuring prolonged survival. The therapeutic landscape has been revolutionized in recent years, where venesection and hydroxycarbamide associated with antiplatelet therapy have a central role and are now accompanied by other drugs, such as interferon and Janus kinase inhibitors. On

Возвращенная Множественная миелома в гастроинском кишечном тракте с аберрантным выражением CD3: доклад по делу.

В этом докладе описывается редкий случай рецидива множественной миэломы в желудочно-кишечном тракте с аберрантным выражением CD3. При наличии острой почечной недостаточности у пациента были аномальные вычисления томографического сканирования брюшной полости и таза. После этого колоноскопия обнаружила множество полипов и масс. Гистологический анализ биопсии one Из масс обнаружил диффузный атипичный клеточный инфильтрационный процесс с недифференцированной морфологией в субмукозе, который был положительным для CD3, CD4, слабого и переменного CD79a, CD138, BCL2, CMYC, MUM1, виментина и моноклонно

Совпадение в полном тексте источника
… Introduction Multiple myeloma (MM) is a hematologic neoplasm predominantly affecting the elderly population (median age of 70 years old), comprising approximately 10% of all hematologic malignancies [ 1 ], and is characterized by clonal expansion of plasma cells. … These histologic features were consistent with our case and yielded a broad differential diagnosis including poorly differentiated carcinoma and high-grade hematologic neoplasms. …

Impact of germline predisposition genes to hematologic malignancies on transplant outcomes and donor selection.

INTRODUCTION: Germline predisposition gene mutations may influence outcomes in patients undergoing hematopoietic stem cell transplantation (HSCT). METHODS: This retrospective study of 558 patients undergoing HSCT (allo-HSCT in 557 cases, auto-HSCT in 1 case) evaluated the impact of germline predisposition gene mutations on outcomes. RESULTS: Enrichment of HAVCR2 mutations in B-NHL and UNC13D mutations in MDS was associated with poorer prognosis. While homozygous mutation carriers (7.5%) overall did not have reduced survival, their outcomes were significantly better with unrelated versus rela

Advances in Leukemia detection and classification: A Systematic review of AI and image processing techniques.

BACKGROUND: Leukemia, a heterogeneous group of blood cancers, poses significant challenges to global health due to its complexity, diverse risk factors, and variable outcomes. Accurate and early diagnosis is critical but remains a significant hurdle, particularly in low-resource settings. Recent advancements in artificial intelligence (AI) and image processing offer transformative solutions to improve leukemia detection and classification, addressing limitations in traditional diagnostic methods. METHODS: This study systematically reviewed over 25,000 scientific articles sourced from Scopus,

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.

OBJECTIVE: Vacuoles E1 enzyme X-linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality. METHODS: Given the variability in disease presentation and the limited number of studies to date, no clinical documents currently exist to provide guidance to health care providers about the management of VEXAS. To address this gap, we formed an international multidisciplinary panel of VEXA

Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis.

Patient populations, including those with hematological malignancies, have different responses to COVID-19 vaccines. This study aimed to quantitatively analyze the efficacy and safety of COVID-19 mRNA vaccines in patients with hematological malignancies. Studies reporting on the efficacy and safety of COVID-19 mRNA vaccines in cohorts with hematological malignancies compared to healthy controls were systematically searched in four databases. Meta-analysis and subgroup analyses were performed to generate quantitative synthesis. Fifteen studies with 2,055 cohorts with hematological malignancies

Deciphering the Patterns of Dual Primary Cases Registered at the Hospital-Based Cancer Registry: First Experience from Rural Cancer Center in North India.

Objectives The objective is to present the patterns of dual primary malignancies diagnosed at the Pathology Laboratory of Cancer Hospital with the support from hospital-based cancer registry (HBCR), Sangrur, Punjab, India for the years 2018 and 2019. Methods HBCR abstracts data from electronic medical records. Trained cancer registry staff abstracts cases in standard pro forma. Dual primary was coded as per the International Agency for Research on Cancer rule and was rechecked by the pathologist. Statistical Analysis Data about multiple primary was entered and documented in an Excel sheet. Tim

Mapping the research landscape of myelodysplastic syndromes: a scientometric analysis (2014-2025).

This scientometric study critically evaluates the global evolution of myelodysplastic syndromes (MDS) research from 2014 to 2025, aiming to integrate fragmented knowledge and identify emerging trends. A scientometric analysis was conducted using data retrieved from the Web of Science Core Collection on August 2, 2025. The search was restricted to "article" and "review" in English containing "Myelodysplastic syndrome" or "Myelodysplastic syndromes" in the abstract, covering the period from January 1, 2014 onward. Scientometric tools (VOSviewer, CiteSpace, R-bibliometrix) were employed to analyz

Epigenetics in myeloproliferative neoplasms.

The myeloproliferative neoplasms (MPNs) are a group of acquired clonal disorders where mutations drive proliferative disease resulting in increased blood counts and in some cases end-stage myelofibrosis. Epigenetic changes are the reversible modifications to DNA- and RNA-associated proteins that impact gene activity without changing the DNA sequence. This review summarizes mechanisms of epigenetic changes and the nucleosome. The drivers and epigenetic regulators in MPNs are outlined. In MPNs, distinct patterns of epigenetic dysregulation have been seen in chronic and in advanced phases. Methyl

A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023.

BackgroundBispecific antibody (BsAb)-based cancer immunotherapy has provided new avenues for the treatment of various malignancies. The approval of Blinatumomab has encouraged further investigation into these treatments, and a series of preclinical and clinical trials have been conducted, together with the publication of numerous articles. Here, the knowledge structure of BsAb-based cancer immunotherapy is summarized using bibliometric analysis to provide in-depth insight into current research trends and foci.MethodsThe studies included in the bibliometric analysis of BsAbs in cancer immunothe

Orbital Plasmacytoma as Initial Presentation of Multiple Myeloma.

Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells in the bone marrow. It represents approximately 10% of hematologic malignancies and is the most common primary bone malignancy. This disease usually occurs between the ages of 40 and 70, although it is more frequently seen in patients over 65 years of age. On the other hand, extramedullary plasmacytoma-related diseases have a global annual incidence of three per 100,000 people. Orbital involvement in MM is considered rare. Orbital plasmacytomas represent less than 1% of all orbital lesions,

Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France.

AbstractMalignant histiocytoses (MH) are rare and poorly understood cancers, with no established therapeutic guidelines. We conducted a national retrospective study of MH diagnosed in France between 2000 and 2023. All cases underwent centralized histological review, and several malignant tumors with a stroma highly enriched in histiocytes were excluded. In total, 141 patients were included, with a median age of 62 years (range, 1-87). The cases comprised either primary MH (64%) or MH associated with other hematologic malignancies (36%). Phenotypes corresponded to histiocytic (43%), interdigita

Совпадение в полном тексте источника
… Instead, the Histiocyte Society considered the association of MH with another hematologic neoplasm (secondary MH) as a distinct and relevant subtype, separate from de novo MH (primary MH). … The respective proportion of the type of associated hematologic neoplasms may depend on the number of children or young adults referred to the expert centers. …

Concurrent B-cell acute lymphoblastic leukemia and plasma cell neoplasm with plasmablastic features supporting divergent evolution from a shared precursor: a case report.

BACKGROUND: B-cell malignancies comprise a biologically diverse group of neoplasms, with only rare reports describing the co-occurrence of two distinct lymphoid entities. While concurrent presentation of mature B-cell neoplasms has been documented, the simultaneous occurrence of B-cell acute lymphoblastic leukemia (B-ALL) and plasma cell neoplasm (PCN) has previously been reported rarely. Such cases may provide insight into the clonal architecture and evolutionary pathways underlying lymphoid malignancies. CASE PRESENTATION: We report a 76-year-old man presenting with cytopenias and leukocyto

Next Generation Therapeutics for the Treatment of Myelofibrosis.

Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis, and a propensity towards transformation to acute leukemia. JAK inhibitors are the only approved therapy for myelofibrosis and have been successful in reducing spleen and symptom burden. However, they do not significantly impact disease progression and many patients are ineligible due to coexisting cytopenias. Patients who are refractory to JAK inhibition also have a dismal survival. Therefore, non-JAK inhibitor-based therapies are being explored in pre-clinical and clini

Реальная эффективность и терпимость комбинированной терапии на основе ixazomib в современных множественных миеломах и других плазменных новообразованиях клеток.

Ixazomib — пероральный протеазонный ингибитор для реактивной/охотничьей множественной миеломы (RRMM). Цель нашего исследования состояла в анализе эффективности и терпимости комбинированной терапии на основе ixazomib. Methods Мы провели ретроспективный анализ в одном центре 126 - пациенты с опухолью RRMM и другими плазменными клетками. 65 лет, с медианой two :: предыдущая терапия и 16.7% был тройным рефрактом. Общая доля ответивших (ОРС) 52.5%; у трехклассных пациентов, страдающих рефрактом, ОРР значительно ниже, чем у нереактивных органов контроля (см.10.5% vs. 60.2%, р 2 была увязана с более

Distress Screening among Patients with Hematological Malignancies: A Descriptive Cross-sectional Study.

IntroductionDistress is a major concern during diagnosis and treatment of hematological malignancies. The Distress Thermometer is a commonly used screening tool to detect distress. The objectives of this study was to know the prevalence and identify distress score among patients with hematological malignancies in Nepal.MethodsA descriptive cross sectional study was carried out at the Hematology Unit of Civil Service Hospital after obtaining an ethical approval from the Institutional Review Committee (reference number 931/076/077). A convenient sampling technique was used for this study. Statis

Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies.

Cancer represents the leading cause of disease-related death and treatment-associated morbidity in children with an increasing trend in recent decades worldwide. Nevertheless, the 5-year survival of childhood cancer patients has been raised impressively to more than 80% during the past decades, primarily attributed to improved diagnostic technologies and multiagent cytotoxic regimens. This strong benefit of more efficient tumor control and prolonged survival is compromised by an increased risk of adverse and fatal late sequelae. Long-term survivors of pediatric tumors are at the utmost risk fo

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy. DIAGNOSIS: Diagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies such as karyotype, flow cytometry, and molecular genetics is usually complementary and may he